Navigation Links
Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
Date:4/14/2009

Expects to qualify for 180 days of sole marketing exclusivity

PITTSBURGH, April 14 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Hoffmann-La Roche Inc. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Capecitabine Tablets, 150 mg and 500 mg, the generic version of Xeloda(R) Tablets, a chemotherapy treatment for breast and colorectal cancer.

Mylan believes it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for the product and expects to qualify for 180 days of sole marketing exclusivity once final FDA approval is obtained. Hoffmann-La Roche filed a lawsuit April 8 in the U.S. District Court for the District of New Jersey alleging infringement of U.S. Patent No. 5,472,949.

Xeloda Tablets, 150 mg and 500 mg, had approximately $447 million in sales for the 12 months ending Dec. 31, 2008, according to IMS Health. Currently, Mylan has 117 ANDAs pending FDA approval, 33 of which are potential first-to-file opportunities.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first-to-file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to de
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
2. Mylan Announces Clarinex(R) Settlement Agreement
3. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
4. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
5. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
6. Mylan Announces Transition of Chief Financial Officer
7. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
8. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
9. Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... (PRWEB) September 16, 2014 SAMHSA, the federal ... mission a reduction of the impact of substance abuse and ... on the SAMHSA website in September is National Recovery Month, ... honor the gains made by those individuals in recovery. ... to addiction treatment in an effort to help those with ...
(Date:9/16/2014)... REDWOOD CITY, CALIF. (PRWEB) September 16, 2014 ... contact center and customer service solutions, announced today ... Group Excellence in Learning Award for the creation ... for independent contractor agents. Brandon Hall Group honors ... strategies, modalities, processes, systems and tools that have ...
(Date:9/16/2014)... Former Major League Baseball relief pitcher ... heart transplantation surgery at Allegheny General Hospital (AGH) on ... of his 16-year baseball career with the Pittsburgh Pirates ... Root Sports Pittsburgh, was discharged home on Friday, September ... surgical director of AGH’s heart transplant program. , “Mr. ...
(Date:9/16/2014)... inoperable, early-stage lung cancer who receive stereotactic body ... of 40 percent, according to research presented today ... 56th Annual Meeting. Such a positive survival rate ... in poor tumor control for patients with inoperable ... RTOG 0236, originally published in 2010 , and ...
(Date:9/16/2014)... to be on the heavy side. Researchers at the ... seven in every ten obese adults underestimate how much ... much less often. Mothers of overweight or obese children ... misjudge their obese mothers, size, says lead author Tracy ... in the Journal of General Internal Medicine , ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 2Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 3Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 2Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 3Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 4Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3Health News:Poor body size judgement can lead to increased tolerance of obesity 2
... Your Medicines and You, Event Provides Free Pharmacist Reviews ... Mistakes, CHICAGO, Oct. 31 The following is ... one of the leading causes of death for,individuals over ... are teaming,up this Thursday to help people better manage ...
... Oct. 31 Varian, Inc.,(Nasdaq: VARI ) ... TOP-DNA and TOP-RNA, for the purification of,synthetic oligonucleotides ... used by life science researchers to,study the functions ... to work,properly, salts and incomplete products need to ...
... 11:01 AM October 31, 2007, WASHINGTON, ... of AARP told lawmakers what American families,already know ... our country is,the skyrocketing costs of health care., ... CEO Bill Novelli testified at a Senate Budget ...
... Another Scientific Review ... ... DENVER, Oct. 31 "The WCRF/AICR recommendations about,red meat and cancer are unsubstantiated ... red meat in a healthy,diet that far outweigh anything we,ve seen today. "There ...
... Open-Bore, Design to Bring High-Resolution MR Imaging to More Patients ... ... MALVERN, Pa., Oct. 31 Combining 3 Tesla strength and,sensitivity with a ... a 3 Tesla (T) MRI system with a 70 cm open bore ...
... to ways to treat injury, stroke and even Alzheimer,s, experts ... new U.S. study involving mice suggests the brain,s own stem ... injury. , These neural stem cells work by protecting existing ... team at the University of California, Irvine, were able to ...
Cached Medicine News:Health News:Varian, Inc. Offers New Products for the Rapid Purification of Synthetic Oligonucleotides. 2Health News:AARP CEO Bill Novelli Tells Lawmakers: Controlling Health Care Costs Key to Budget Reform 2Health News:NCBA Statement on 2007 WCRF/AICR Second Expert Report on Food, Nutrition and Physical Activity and the Prevention of Cancer: 2Health News:3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI 2Health News:3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI 3Health News:3 Tesla + 70 cm + Tim = The Most Exciting Equation in MRI 4Health News:Stem Cells Restore Memory in Mice 2Health News:Stem Cells Restore Memory in Mice 3
(Date:9/16/2014)... LONDON , Sept. 16, 2014 ... wound closure market, Frost & Sullivan recognises Incisive ... Award for Customer Value Leadership. Incisive Surgical,s uniquely-designed, ... closure technology that eliminates the need for patients ... punctures and staple removal  that may result in ...
(Date:9/16/2014)... Sept. 16, 2014  Synereca Pharmaceutics, Inc. ... orally active drugs that restore or increase ... a $1.4 million convertible debt financing. Accele ... sciences accelerator Accele Biopharma, Inc., led the ... nationally recognized private not-for-profit corporation focused on ...
(Date:9/16/2014)... Sept. 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), ... of chronic pain, announced today that it has entered ... (MSKCC) in a series of animal studies for levorphanol, ... extended release form of levorphanol.  Gavril Pasternak, MD, PhD, ... Dr. Pasternak said, "Levorphanol is a ...
Breaking Medicine Technology:Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... Study Success in Using Virus Enzyme to Treat Mouse ... Be Used to,Prevent Both Ear Infection and Pneumonia in ... -- Parents might one,day give their children a weekly ... them from getting a severe middle ear,infection, based on ...
... the Drug Improves Memory, SARASOTA, Fla., March 22, ... it has received positive,preliminary results in its major ... application for the treatment of Alzheimer's,disease. The clinical ... first human clinical study conducted by a,Florida-based research ...
Cached Medicine Technology:Viral Enzyme Recruited in Fight Against Ear Infection 2Viral Enzyme Recruited in Fight Against Ear Infection 3Sarasota's Roskamp Institute Announces Positive Safety Data in,Human Clinical Study for Alzheimer's Disease 2
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
... German Craftsmanship have produced ... in the world. Ocutek® ... to you! Only holders ... certificate, which requires and ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
Medicine Products: